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Apoptosis represents one of the most important forms of cell death in higher organisms
and is typically dysregulated in human cancers, including pediatric tumors.This implies that
ineffectiveengagementofcelldeathprogramscancontributetotumorformationaswellas
tumor progression. In addition, the majority of cytotoxic therapeutic principles rely on the
activation of cell death signaling pathways in cancer cells. Blockade of signaling networks
that lead to cell death can therefore confer treatment resistance. A variety of genetic
and epigenetic events as well as dysfunctional regulation of signaling networks have
been identiﬁed as underlying causes of cell death resistance in childhood malignancies.
Apoptosis pathways can be therapeutically exploited by enhancing proapoptotic signals
or by neutralizing antiapoptotic programs. The challenge in the coming years will be
to successfully transfer this knowledge into the development of innovative treatment
approaches for children with cancer.
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INTRODUCTION
It is now well-appreciated that there are several modes of cell
death in higher organisms (Lockshin and Zakeri, 2007). Among
them,apoptosis represents a key cellular program which is associ-
ated with a number of characteristic biochemical features as well
as morphological parameters (Lockshin and Zakeri, 2007). The
efﬁcacy of most anticancer therapies resides in their ability to
engage endogenous cell death programs in cancer cells (Fulda and
Debatin,2006).Thisimpliesthatablockadeof celldeathpathways
provides an effective means to evade the cytotoxicity of current
treatment approaches. Thus,a better understanding of the molec-
ular events that are responsible for the dysregulation of cell death
signaling networks in pediatric malignancies is expected to open
new opportunities for the development of innovative treatment
strategies.
APOPTOSIS SIGNALING NETWORKS
A core apoptotic machinery is responsible for the initiation and
execution of programmed cell death by apoptosis (Fulda and
Debatin, 2006). Accordingly, the death receptor (extrinsic) path-
way and the mitochondrial (intrinsic) pathway represent the two
principal signaling cascades that fuel into the activation of a com-
mon downstream effector route of apoptosis that eventually leads
tothedismantlingof thecell(Figure1;Fulda and Debatin, 2006).
In the executioner phase of apoptosis, a family of proteases, i.e.,
caspases, represent core effector molecules of apoptosis that con-
tribute to the ﬁnal steps of apoptotic cell death by cleaving key
cellular substrates, for example components of the cytoskeletal
apparatus and nuclear DNA (Taylor etal., 2008).
As far as the death receptor (extrinsic) pathway of apopto-
sis is concerned, the binding of soluble ligands of the tumor
necrosis factor (TNF) family of ligands or agonistic antibodies
to death receptors of the TNF receptor superfamily on the cell
surfaceengagesasignalingcascadethateventuallyleadstocaspase
activationwithallsubsequentsubcellularevents(Figure1;Ashke-
nazi, 2008). Following ligand/receptor interaction, a multiprotein
complex is formed at the plasma membrane that contains acti-
vated death receptors as well as intracellular signaling molecules
that are recruited upon activation, for example FAS-associated
death domain protein (FADD) and caspase-8 (Ashkenazi, 2008).
This multiprotein complex is called the death-inducing signaling
complex (DISC) and provides a signaling platform for activa-
tion of caspase-8 (Ashkenazi, 2008). Once activated, caspase-8
transmits the death signal by cleaving and activating downstream
effector caspases such as caspase-3. Alternatively, caspase-8 can
cleave other substrates besides caspases for example Bid, which
resultsinthegenerationof tBid,acleavageproductwithincreased
proapoptotic activity. tBid, in turn, translocates to mitochon-
drial membranes to initiate cytochrome c release. Various stress
signals including DNA damage and hypoxia can engage the
mitochondrial (intrinsic) pathway, leading to permeabilization
of mitochondrial membranes and the release of proapoptotic
proteins from the mitochondrial intermembrane space into the
cytosol (Figure 1; Fulda etal., 2010). For example, the release
of cytochrome c from the mitochondria initiates the formation
of a multiprotein complex consisting of Apaf-1, cytochrome c
and caspase-9 which drives caspase-9 activation in the cytosol.
Alternatively, the release of Smac (second mitochondrial acti-
vator of apoptosis) fosters caspase activation and apoptosis by
neutralizing Inhibitor of Apoptosis (IAP) proteins (Fulda and
Vucic, 2012).
MOLECULAR TARGETED STRATEGIES TO EXPLOIT
APOPTOSIS PATHWAYS
Since the engagement of apoptosis signaling cascades can trig-
ger cell death very efﬁciently and rapidly, there are also various
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FIGURE 1 | Scheme of apoptosis pathways.There are two key apoptosis
signaling pathways, i.e., the death receptor (extrinsic) pathway and the
mitochondrial (intrinsic) pathway. Stimulation of death receptors by their
cognate ligands leads to activation of caspase-8, which either directly
activates downstream caspases or initiates the mitochondrial pathway by
cleaving Bid. Engagement of the intrinsic pathway results in the release of
mitochondrial proteins such as cytochrome c or Smac into the cytosol,
which in turn promotes activation of caspase-3 and apoptosis.
brakes in order to ensure that accidental engagement of this
cellularsignalingnetworkdoesnothavedetrimentaleffectsoncell
viability (Fulda, 2009). Accordingly, a large variety of apoptosis-
inhibiting factors have been identiﬁed that prevent the execution
of the full cell death program upon accidental engagement of
cell death pathways. While these antiapoptotic factors constitute
endogenous regulators for the ﬁne tuning of the system, they
are frequently misused by human cancers to block signaling to
cell death and to evade the induction of apoptosis. For example,
genetic or epigenetic events can lead to aberrant overexpression
of antiapoptotic molecules or, alternatively, to silencing or inac-
tivation of proapoptotic factors with the result of a blockade of
apoptosis signaling pathways (Fulda, 2009). This implies that a
better understanding of the molecular events that are responsi-
ble for the inactivation of cell death programs in human cancers
can provide the basis for the development of molecular targeted
therapies in order to efﬁciently elicit apoptotic cell death as a new
therapeuticstrategy.Theideatoselectivelytargetapoptosissignal-
ingpathwaysinordertoeitherdirectlyengagecelldeathprograms
or to bypass resistance to apoptosis by neutralizing the factors
that block apoptosis has in recent years already been transferred
into the development of innovative treatment approaches. These
concepts are currently under preclinical and clinical evaluation.
On theoretical grounds, these approaches can be divided accord-
ing to their primary mode of action, e.g., depending on whether
they engage proapoptotic signals or antagonize antiapoptotic
factors.
STRATEGY 1: ENHANCING PROAPOPTOTIC SIGNALS
One strategy to target apoptosis signaling pathways for the treat-
ment of cancers resides in the direct activation of proapoptotic
signaling pathways (Figure 1). The best know example of direct
engagement of apoptosis pathways is the use of death receptor
ligands, which bind to the corresponding death receptors on the
cell surface. Since death receptors have a direct link to apoptosis
signaling pathways, this approach can directly engage the apop-
totic machinery. Among the death receptors and their ligands,the
TRAIL/TRAIL receptor system has gained most attention, since it
preferentially triggers cell death in cancer cells compared to non-
malignant cells,providing some tumor selectivity (Ashkenazi and
Herbst, 2008; Humphreys and Halpern, 2008). There are four
membrane-bound TRAIL receptors, two of which transmit the
apoptotic signal to intracellular signaling pathways of apoptosis
(Ashkenazi,2008).Bycomparison,twoTRAILreceptorsrepresent
decoy receptors that bind TRAIL, but do not produce a proapop-
totic signal and can even antagonize TRAIL-mediated apoptosis
(Ashkenazi, 2008).
In order to target the two proapoptotic TRAIL receptors,
soluble TRAIL as well as antibodies directed selectively against
T R A I Lr e c e p t o r1o rT R A I Lr e c e p t o r2h a v eb e e nr e p o r t e dt o
elicit apoptosis in childhood malignancies, e.g., in neuroblas-
toma, rhabdomyosarcoma, Ewing’s sarcoma and leukemia (Petak
etal., 2000; Van Valen etal., 2000; Kontny etal., 2001; Fulda etal.,
2002a; Ehrhardt etal., 2003; Yang and Thiele, 2003; Fulda, 2008;
Kang etal., 2011; Abhari etal., 2012). However, soluble TRAIL or
receptorantibodiesareoftennotsufﬁcientasmonotherapytosup-
press tumor growth. For example, a fully humanized monoclonal
antibody directed against TRAIL receptor 1, i.e., mapatumumab,
was tested within the Pediatric Preclinical Testing Program, a
National Cancer Institute initiative to identify compounds that
should be prioritized for clinical evaluation in pediatric cancer
(Smith etal., 2010). Limited cytotoxic effects were reported for
various pediatric cancer cell lines, when mapatumumab was used
incellculturestudies(Smithetal.,2010).Someantitumoractivity
in vivo was reported for mapatumumab with signiﬁcant differ-
ences in event-free survival of mice treated with mapatumumab
in some solid pediatric cancer models,for example osteosarcoma,
neuroblastoma, and glioblastoma (Smith etal.,2010).
Based on these in vitro and in vivo studies showing that
monotherapy with TRAIL ligands or TRAIL receptor antibodies
are not sufﬁcient to cause tumor regression and sustained control
oftumorgrowthinthemajorityofchildhoodcancers,anumberof
different combination therapies were developed. One promising
approach resides in the combination of TRAIL receptor agonists
together with conventional chemotherapeutics (Van Valen etal.,
2003; Komdeur etal.,2004; Muhlethaler-Mottet etal.,2004;Wang





with chemotherapy has been pursued in various malignancies
including childhood tumors.
The evaluation of TRAIL receptor agonists against pediatric
cancers is hampered by the fact that only a few studies have so far
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been conducted using primary tumor samples instead of estab-
lished cancer cell lines. Such studies on primary tumor material
are especially relevant to evaluate the antitumor activity of TRAIL
receptoragonists,sinceitiscurrentlyuncleartowhatextentestab-
lished cancer cell lines do in fact resemble the clinical situation.
Studies testing TRAIL receptor agonists against primary tumor
samples include experiments with primary neuroblastoma cells
derived from children with neuroblastoma (Abhari etal., 2012).
Soluble TRAIL as well as TRAIL receptor 2 agonistic antibodies
were shown to trigger apoptosis in primary neuroblastoma cells,
in particular in combination with molecular targeted therapeu-
tics,i.e.,Smac peptides,IAP antagonists,or proteasome inhibitors
(Fulda etal., 2002b; Naumann etal., 2011; Abhari etal., 2012).
Furthermore,primary acute lymphoblastic leukemia (ALL) blasts
obtained from children with ALL were tested for their sensitiv-
ity toward TRAIL (Ehrhardt etal.,2003; Fakler etal.,2009).While
50%oftheseprimarysamplesrespondedtotreatmentwithTRAIL
with apoptosis, the remaining 50% remained resistant toward
TRAIL (Ehrhardt etal., 2003). Of note, some resistant samples
eventually exhibited an increase in proliferation in response to
TRAIL treatment compared to untreated controls, in line with
the observation that TRAIL can paradoxically stimulate non-
apoptotic signaling pathways proliferation in apoptosis-resistant
cancers, for example by activating nuclear factor-kappaB (NF-
κB; Ehrhardt etal., 2003). The ﬁrst phase I clinical trial to
evaluate a TRAIL receptor agonist against pediatric cancers was
recently completed using the TRAIL-R2 monoclonal antibody
lexatumumab in children with refractory solid tumors (Table 2).
STRATEGY 2: NEUTRALIZING ANTIAPOPTOTIC PROTEINS
Another approach to exploit apoptosis signaling pathways for the
treatmentof pediatriccancersresidesintheneutralizationof anti-
apoptotic mechanisms that block apoptosis signaling. Depending
on the status of oncogenic action of a particular tumor, this
approach will either engage cell death programs or will have to be
combined with additional cytotoxic principles that directly trig-
ger cell death. Key negative regulators of apoptosis comprise the
antiapoptotic proteins of the Bcl-2 family and IAP proteins.
IAP PROTEINS AS THERAPEUTIC TARGETS IN PEDIATRIC
CANCERS
Inhibitor of Apoptosis proteins comprise eight human analogs
including X chromosome-linked inhibitor of apoptosis protein
(XIAP), cIAP1, cIAP2, survivin, apollon, livin/melanoma-IAP
(ML-IAP), neuronal apoptosis inhibitory protein (NAIP), and
IAP-like protein-2 (ILP-2) (Table 1; Fulda and Vucic, 2012). The
baculoviralIAPrepeat(BIR)domainrepresentstheunifyingstruc-
tural motif that is present in all IAP proteins. In addition to this
BIR domain, additional functional domains of IAP proteins exist
in some but not all family members. For example,the really inter-
estingnewgene(RING)domainexertsE3ubiquitinligaseactivity
andisinvolvedinubiquitination.Despitetheirname,IAPproteins
vary in their ability to block apoptosis. Among the IAP proteins,
XIAP is considered to possess the most prominent antiapoptotic
activityandinhibitscaspaseactivationbybindingtocaspase-3,-7,
and -9 (Eckelman etal., 2006). IAP proteins that harbor a RING
domaincantriggerproteasomaldegradationofotherIAPproteins
Table 1 | List of human IAP proteins.







BIRC7 ML -IAP , Livin
BIRC8 ILP2, hILP2
or caspases via their E3 ligase activity (Fulda and Vucic, 2012). In
addition, K63-linked ubiquitination results in modulation of sig-
nal transduction and,for example,activation of NF-κB by cellular
inhibitor of apoptosis protein (cIAP) proteins.
Since IAP proteins block downstream effector pathways of
apoptosis by inhibiting caspase activation and also impinge on
critical cell survival pathways including NF-κB signaling, they
represent promising targets for therapeutic intervention. Accord-
ingly, a number of different approaches have been pursued over
the last years to develop therapeutic strategies directed against
IAP proteins. For example, Smac peptides and Smac mimet-
ics have been developed to neutralize IAP proteins (Fulda and
Vucic, 2012). These small molecules resemble the endogenous
Smac protein, an endogenous antagonist of IAP proteins. Under
physiological conditions, Smac resides within the mitochon-
drial intermembrane space. Upon the induction of apoptosis,
Smac is released from the mitochondrial intermembrane space
into the cytosol where it binds to IAP proteins and neutral-
izes them. Similar to Smac-related compounds, small-molecule
IAP antagonists have been designed that similarly bind to
IAP proteins and antagonize their function (Fulda and Vucic,
2012). Smac mimetics or IAP antagonists have been reported
to either directly trigger apoptosis or to enhance apoptosis in
response to death receptor ligands, cytotoxic chemotherapeu-
tics or γ-irradiation in various childhood cancers, including
leukemia, neuroblastoma, rhabdomyosarcoma, and glioblas-
toma (Fulda etal., 2002b; Fakler etal., 2009; Loeder etal., 2010;
Abhari etal., 2012; Loder etal., 2012; Wagner etal., 2012). In
a ﬁrst proof-of-concept study in an intracranial mouse model
of glioblastoma, the combined administration of Smac mimetic
together with TRAIL resulted in complete eradication of glioblas-
toma (Fulda etal., 2002b). Similarly, IAP antagonists together
with TRAIL exerted antileukemic activity in a non-obese dia-
betic/severe combined immunodeﬁcient (NOD/SCID) mouse
model of ALL and also acted in concert to trigger apoptosis
in ALL cell lines as well as in primary blasts obtained from
children with ALL (Fakler etal., 2009). Furthermore, IAP antag-
onists synergized together with TRAIL receptor 2 antibodies,
i.e., lexatumumab, to trigger apoptotic cell death in neuroblas-
toma cells, including primary neuroblastoma cultures derived
from patient samples (Abhari etal., 2012). Similar synergistic
antitumor activity was observed for IAP antagonists together
www.frontiersin.org February 2013 | Volume 3 | Article 22 | 3“fonc-03-00022” — 2013/2/12 — 15:10 — page4—# 4
Fulda Targeting apoptosis pathways in pediatric cancers
with lexatumumab against rhabdomyosarcoma. Besides TRAIL,
IAP antagonists were also reported to act in concert with




Besides its function in apoptosis,survivin also plays an important
role in the regulation of mitosis. As far as childhood malignancies
are concerned, survivin has gained considerable attention, since
it is located on 17q25, a chromosomal region that is frequently
ampliﬁed in neuroblastoma (Islam etal., 2000). Accordingly,
overexpressionof survivinwasassociatedwithadvance-stageneu-
roblastoma as well as poor prognosis (Adida etal., 1998; Islam
etal.,2000;Azuhata etal.,2001; Ito etal.,2005; Miller etal.,2006).
Besides neuroblastoma, also childhood leukemia exhibits high
expression of survivin which correlated with an enhanced risk of
relapse(Troegeretal.,2007). Of note,high-riskpediatricALLalso
correlatedwithlowlevelsof survivin-2B,sincethisisoformof sur-
vivin was found to promote rather than inhibit apoptosis (Troger
etal., 2007). It is interesting to note that survivin has been used
as a therapeutic target for immunotherapeutic strategies (Cough-
lin etal., 2006). For example, survivin served as tumor-associated
antigene for stimulation of cytotoxic T cells.Also,a DNA vaccina-
tion based on survivin-associated peptides was designed that led
to suppression of tumor growth upon prophylactic vaccination in
a neuroblastoma in vivo mouse model (Fest etal., 2009). In chil-
dren with relapsed ALL, a phase I clinical trial testing EZN-3042,
an investigational agent that inhibits survivin protein expression,
together with re-induction chemotherapy was recently conducted
(Table 2).
Bcl-2 PROTEINS AS THERAPEUTIC TARGETS IN PEDIATRIC
TUMORS
Proteins of the Bcl-2 family comprise both pro- and antiapoptotic
members (Table 3) and play an important role in the regula-
tion of the intrinsic pathway of apoptosis (Adams and Cory,
2007). Accordingly, pro- and antiapoptotic Bcl-2 proteins are
critical regulators of mitochondrial outer membrane permeabi-
lizationbyregulatingthereleaseof mitochondrialintermembrane
proteins into the cytosol. Antiapoptotic Bcl-2 proteins such as
Bcl-2, Bcl-XL, and Mcl-1 are often overexpressed in human
cancers including childhood malignancies. Since the efﬁcacy
of chemotherapy largely depends on intact apoptosis signaling
pathways, in particular mitochondria-mediated apoptosis over-
expression of antiapoptotic Bcl-2 proteins has been linked to
chemoresistance. Consequently, targeting of antiapoptotic Bcl-2
Table 2 | Examples of clinical trials targeting apoptosis pathways in
pediatric cancers.
Agent Target Trial stage Condition Identiﬁer # # #
Lexatumumab TRAIL -R2 Phase I Pediatric solid tumors NCT00428272
G3139 Bcl-2 Phase I Pediatric solid tumors NCT00039481
EZN-3042 Survivin Phase I Pediatric ALL NCT01186328












proteins is considered to provide a promising approach for
chemosensitization of human cancers (Fulda etal., 2010). To
target antiapoptotic Bcl-2 proteins, small-molecule inhibitors
have been developed. For example, ABT-737 represents such a
small-molecule inhibitor that binds to Bcl-2, Bcl-XL, and Bcl-
w( Oltersdorf etal., 2005). The corresponding orally available
analog ABT-263 was evaluated by the Pediatric Preclinical Test-
ing Program (Lock etal., 2008). Interestingly, the most potent
antitumor activity of ABT-263 was observed against childhood
ALL both in vitro and in vivo with complete remission in 50%
of cases (Lock etal., 2008). In addition, ABT-737 potentiated
chemotherapy-mediated cell death, for example together with
standard cytotoxic compounds used in childhood ALL includ-
ing vincristin, L-asparaginase, and glycocorticoids (Kang etal.,
2007). ThiscooperativeantileukemicactivityofABT-737together
with chemotherapeutics was even observed in cases of drug resis-
tance (Kang etal., 2007), indicating that the addition of ABT-737
may overcome some forms of chemoresistance in ALL. However,
Bcl-XL-targeting compounds can also exert mechanism-based
toxicity by inducing platelet death and subsequently thrombo-
cytopenia (Mason etal., 2007), which may limit their clinical
use in childhood cancers. Moreover, BH3 peptidomimetics that
antagonize antiapoptotic Bcl-2 proteins showed antitumor activ-
ityassingleagentsagainstneuroblastoma(Goldsmithetal.,2006).
Interestingly, high expression levels of Bcl-2 or Mcl-1 correlated
with advanced disease in neuroblastoma (Lestini etal., 2009).
Knockdown studies underscored the important role of Mcl-1 for
chemoresistance, since downregulation of Mcl-1 conferred sensi-
tivity to chemotherapeutics. In vitro proﬁling of neuroblastoma
cells using BH3-domain peptides revealed that, in addition to
Mcl-1, also other antiapoptotic Bcl-2 proteins can confer resis-
tance to chemotherapy (Goldsmith etal.,2010). In addition to the
small-molecule inhibitors, also Bcl-2 antisense oligonucleotides,
for example G3139,showed antitumor activity in pediatric malig-
nancies.Forexample,aphaseItrialwasconductedinchildrenwith
recurrent solid malignancies together with chemotherapeutics
(i.e.,doxorubicin,cyclophosphamide)thatdemonstratedbiologic
activity of G3139 (Rheingold etal.,2007; Table 2). Together,these
studies indicate that the mitochondrial pathway of apoptosis may
represent a promising therapeutic target in childhood cancers.
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CONCLUSION
Based on the concept that apoptotic signaling pathways are cen-
tral regulators of cell death in cancers and upon cancer therapy,
dysregulationof thisprogramcanleadtocancerresistance.There-
fore,theidentiﬁcationofmoleculartargetsthatcanbeexploitedin
the design of novel anticancer strategies yielded several promising
targets for therapeutic intervention. Furthermore, these strate-
gies are already under evaluation in early clinical trials. Therefore,
the knowledge on apoptosis signaling pathways and their dereg-
ulation in pediatric malignancies may open new perspectives
for more effective treatment approaches for children with
cancer.
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